Developed in collaboration with the Weizmann Institute of Science, the product has been approved by the Israeli Ministry of Health and is in the final stages of FDA and CE approvals
It will be used as replacement equipment for outdated and problematic CPAP
The company has already signed distribution agreements throughout Poland Canada and with several countries in Europe
Tel Aviv, Israel, December 19, 2022 /PRNewswire/ — A new solution launched by AppScent, an Israeli start-up company, will end the need to deal with the dangerous consequences of sleep apnea symptoms that cause millions of suffering.
The company, led by Yossi Azulaysuccessfully developed, in collaboration with the Weizmann Institute of Science, a unique and revolutionary medical device that combines long-range remote sensors and unique scents to indicate and prevent sleep apnea.
(See how this product works)
One of the most troublesome and dangerous disorders that afflict about a billion people around the world is sleep apnea.
Known outward symptoms of these disorders include, but are not limited to, distracted sleeping, snoring, dry mouth and headaches.
This disorder can lead to much more dangerous and worrisome outcomes, including an increased risk of high blood pressure, stroke, heart failure, obesity, diabetic obesity, and much more.
The way the device works is to clear the airways. Whenever it indicates symptoms of sleep apnea, it clears the airways and prevents sleep apnea.
This new development in Israeli medicine is based on one of the major discoveries of Prof. Sobel. Based on his research, human odor during sleep. When the brain points to a new scent, it starts breathing through the nose. This instinctive reaction renews the breathing process.
One of the main advantages of the development is the fact that it restores the breathing process without disturbing the sleep cycle. In this way, the device does not wake the patient and allows him to sleep better and uninterrupted. This includes the person who sleeps next to the patient.
The company plans to begin general research with the country’s largest health organization soon Israel, Health Services Clalit. Clalit plans to implement a new device in its sleep labs. Thus, for the first time, it will be used as replacement equipment for old and problematic CPAP.
The company has already signed distribution agreements throughout Poland Canada and with several countries in Europe.
The size of the sleep apnea treatment market is estimated at approx USD 5 billion in the United States alone.